Home › Compare › GDPHF vs MRK

GDPHF vs MRK: Dividend Comparison 2026

GDPHF yields 20000.00% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GDPHF wins by $52481917574412746752.00M in total portfolio value
10 years
GDPHF
GDPHF
● Live price
20000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52481917574412746752.00M
Annual income
$51,970,745,957,167,775,000,000,000.00
Full GDPHF calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — GDPHF vs MRK

📍 GDPHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGDPHFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GDPHF + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
GDPHF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GDPHF
Annual income on $10K today (after 15% tax)
$1,700,000.00/yr
After 10yr DRIP, annual income (after tax)
$44,175,134,063,592,610,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, GDPHF beats the other by $44,175,134,063,592,610,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GDPHF + MRK for your $10,000?

GDPHF: 50%MRK: 50%
100% MRK50/50100% GDPHF
Portfolio after 10yr
$26240958787206373376.00M
Annual income
$25,985,372,978,583,888,000,000,000.00/yr
Blended yield
99.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

GDPHF
No analyst data
Altman Z
25.5
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GDPHF buys
0
MRK buys
0
No recent congressional trades found for GDPHF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGDPHFMRK
Forward yield20000.00% ✓3.25%
Annual dividend / share$2.00$3.08 ✓
Payout ratio50%42% ✓
1-year div growth0%5.5% ✓
5-year div CAGR0%8.2% ✓
Portfolio after 10y$52481917574412746752.00M ✓$30.7K
Annual income after 10y$51,970,745,957,167,775,000,000,000.00 ✓$950.29
Total dividends collected$52448189483771600896.00M ✓$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GDPHF vs MRK ($10,000, DRIP)

YearGDPHF PortfolioGDPHF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$2,010,700$2,000,000.00$11,192$351.54+$2.00M → GDPHF
2$377,983,225$375,831,775.70$12,524$392.70+$377.97M → GDPHF
3$66,433,479,469$66,029,037,418.28$14,015$438.65+$66433.47M → GDPHF
4$10,916,985,471,987$10,845,901,648,955.73$15,682$489.96+$10916985.46M → GDPHF
5$1,677,384,363,769,318$1,665,703,189,314,291.80$17,547$547.23+$1677384363.75M → GDPHF
6$240,985,175,079,139,100$239,190,373,809,905,920.00$19,632$611.16+$240985175079.12M → GDPHF
7$32,373,573,631,143,694,000$32,115,719,493,809,017,000.00$21,963$682.53+$32373573631143.68M → GDPHF
8$4,066,766,648,320,630,000,000$4,032,126,924,535,306,000,000.00$24,571$762.18+$4066766648320630.00M → GDPHF
9$477,730,483,406,513,300,000,000$473,379,043,092,810,300,000,000.00$27,486$851.08+$477730483406513344.00M → GDPHF
10$52,481,917,574,412,750,000,000,000$51,970,745,957,167,775,000,000,000.00$30,745$950.29+$52481917574412746752.00M → GDPHF

GDPHF vs MRK: Complete Analysis 2026

GDPHF — Stock

Godolphin Resources Limited operates as a gold and base metal exploration company in Australia. It explores for gold, silver, and copper deposits. The company holds 100% interests in the Mount Aubrey Epithermal Gold, Copper Hill East, and Gundagai North and South Gold-Copper projects located in the Lachlan Fold Belt, New South Wales. It also holds 100% interests in the Mt Bulga, Caledonian, Yeoval, Yallundry, Obley West, Obley North, Cumnock, Narraburra, Temora, Kinross, Sebastopol, Kingsburgh, Calarie, Calarie Central, Calarie Lachlan Mine, Gadara, Goodrich, and Lewis Ponds projects. The company was incorporated in 2019 and is based in Orange, Australia.

Full GDPHF Calculator →

MRK — Healthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this GDPHF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GDPHF vs SCHDGDPHF vs JEPIGDPHF vs OGDPHF vs KOGDPHF vs MAINGDPHF vs JNJGDPHF vs ABBVGDPHF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.